Navigation Links
Stereotaxis Signs Agreement With Leading Leasing Specialist to Offer Alternative Financing to Hospital Customers
Date:3/12/2009

Agreement with Relational Technology Solutions Provides Hospitals with Financial Flexibility for their Purchase of Niobe(R) Magnetic Robotic Systems

ST. LOUIS, March 12 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) today announced that it has reached an agreement with Relational Technology Solutions (RTS) that will allow the Company to offer its hospital customers an alternative financing arrangement for their purchase of Stereotaxis Niobe(R) magnetic robotic systems. Under the agreement, hospitals will be able to fund a Niobe purchase through monthly operating lease payments.

"With this agreement with RTS, Stereotaxis is able to offer hospital administrators enhanced financial flexibility in their purchase of a Stereotaxis system," said Mike Kaminski, Stereotaxis President and CEO. "The operating lease arrangement is an attractive alternative which allows customers to match revenue growth in EP with new technology costs. RTS is very well-regarded in the industry, and we are very happy to be working with the firm to provide our customers with financing alternatives."

"Based on Stereotaxis' unique approach to treating coronary-related diseases and established presence in the healthcare market, Relational Technology Solutions is pleased to enter into a formal partnership with such an innovative company," said Jeff Ehlers, Chief Executive Officer at RTS. "In the current economic environment, it's important that hospitals maintain the financial options necessary to acquire innovative medical technologies that not only improve patient care but are also cost effective. RTS looks forward to working with these organizations and creating custom financing solutions, which will enable them to obtain Stereotaxis technology and maintain a competitive advantage." Relational Technology Solutions currently manages a one billion dollar equipment portfolio spanning medical, IT and telecommunications assets, and provides extensive coverage of the U.S. and Canadian medical equipment capital markets.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

About Forward Looking Statements

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

http://www.stereotaxis.com/


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stereotaxis Announces First Uses of the NAVISTAR(R) RMT THERMOCOOL(R) Catheter
2. Stereotaxis Announces FDA Approval of the NAVISTAR(R) RMT THERMOCOOL(R) Catheter
3. Stereotaxis Reports Fourth Quarter 2008 Financial Results
4. Stereotaxis Annouces First CTO Crossing Procedure With RF PowerAssert(TM) Magnetic Guidewire
5. Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants
6. Stereotaxis Reports Third Quarter 2008 Financial Results
7. Stereotaxis Announces New Management Appointment
8. Stereotaxis Reports Record Second Quarter Revenue
9. Stereotaxis Announces Second Quarter 2008 Earnings Release Date and Conference Call
10. Stereotaxis Magnetic Navigation System Used to Successfully Treat an Inoperable Congenital Heart Defect in a 10-Year Old Patient
11. Stereotaxis Reports Record First Quarter Orders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: